Ambrx Biopharma (AMAM) Short Interest Ratio & Short Volume

Short interest is the volume of Ambrx Biopharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 747,800 shares of AMAM short. 2.09% of Ambrx Biopharma's shares are currently sold short. Learn More on Ambrx Biopharma's current short interest.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ambrx Biopharma: Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.09% of Ambrx Biopharma's floating shares are currently sold short.

Ambrx Biopharma saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 747,800 shares, a decline of 2.1% from the previous total of 763,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Ambrx Biopharma currently has issued a total of 63,150,000 shares. Some of Ambrx Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ambrx Biopharma currently has a public float of 35,790,000 shares.

2.09% of Ambrx Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Ambrx Biopharma: Recursion Pharmaceuticals, Inc. (26.39%), Neumora Therapeutics, Inc. (11.07%), Fusion Pharmaceuticals Inc. (5.73%), Sana Biotechnology, Inc. (21.81%), Twist Bioscience Co. (21.19%), Inhibrx, Inc. (6.18%), Ginkgo Bioworks Holdings, Inc. (19.74%), Kymera Therapeutics, Inc. (15.87%), Beam Therapeutics Inc. (16.00%), ADMA Biologics, Inc. (3.55%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.05 billion), Occidental Petroleum Co. ($3.06 billion), Moderna, Inc. ($2.37 billion), Paramount Global ($2.14 billion), T. Rowe Price Group, Inc. ($2.13 billion), Coinbase Global, Inc. ($2.00 billion), Verisk Analytics, Inc. ($1.94 billion), Extra Space Storage Inc. ($1.77 billion), CarMax, Inc. ($1.59 billion), and Old Dominion Freight Line, Inc. ($1.56 billion). View all of the most shorted stocks.

Short selling AMAM is an investing strategy that aims to generate trading profit from Ambrx Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Ambrx Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AMAM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AMAM, twice per month. The most recent reporting period available is April, 30 2023.